The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study p
about
Statins for primary prevention of venous thromboembolismAdvances in the Study of the Antiatherogenic Function and Novel Therapies for HDLTesting cardiovascular drug safety and efficacy in randomized trialsSunlight exposure and cardiovascular risk factors in the REGARDS study: a cross-sectional split-sample analysis.Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemiaHDL and cognition in neurodegenerative disorders.Niacin for primary and secondary prevention of cardiovascular events.Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parametersEffect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.Lipids, blood pressure, kidney - what was new in 2011?The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotypeBaseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in menTestosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacityTriglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular outcomes in prevalent dialysis patients.Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney diseaseExtended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.Association of Medicare Part D medication out-of-pocket costs with utilization of statin medicationsHDL and cholesterol: life after the divorce?The facts behind niacin.Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.Optimal lipid targets for the new era of cardiovascular prevention.Dyslipidemia: management using optimal lipid-lowering therapy.Niacin as antidyslipidemic drug.Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome.Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.Is there a relationship between lipids metabolism and splenic surgeries?Emerging approaches for the treatment of hypertriglyceridemia.High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular RiskThe role of splenectomy in lipid metabolism and atherosclerosis (AS)
P2860
Q24187238-07056727-CF4E-4037-896E-92E2D19084DDQ26801507-D607A35B-DBF0-473C-BE1E-A8418C5E6FA9Q26849771-85C7F370-105B-4E7A-A2D9-3D2EBA8719B2Q33823811-05560909-DA7D-408A-A844-BC6A8A3FA989Q33935328-9B845233-D517-404A-BCB5-F531BE6CEC9EQ34614842-29D3AC4B-50EE-4568-B696-3C890A330E6BQ34682221-F6B8E0F8-6251-432C-950D-05D7FCFBCD52Q34805517-67A43789-59A2-41B6-B1D1-BC5CF870A15EQ35179226-823FEC08-9CE5-409E-A12F-63F8C6EF6FE4Q35440499-DC67A7C3-1AD4-4B90-8CA9-ECC33C718578Q35667598-EBD206C0-5859-404A-8E5E-42FC6D088581Q35691396-DB876F6D-E1B2-48A7-85EB-CA1C58B3419DQ35784769-92DFD459-F38C-470C-B494-39BB53BA7F83Q35809770-AE469B9F-9A1D-4946-8BFD-FF22519D7C87Q35831025-69922C5E-E96D-4E23-8B9A-B6A0717F0F58Q36020300-43BE4E71-60EE-4FB2-A516-E195400534B0Q36151033-FE0F36C3-D72E-4F63-92B6-F19932E5F2C0Q36471811-D779970F-6B4A-499E-89E8-56CFB08FEA4FQ36950275-7AF106D1-6AD9-42B0-AC67-FF205D38A407Q37050954-37A235D5-9A3A-4B67-AB09-3EDB3741EFF1Q37590250-BB5A87AF-B49E-40F5-9635-8DB56323945AQ37926768-E670F605-D84C-4E61-99C1-FC60521F2491Q37964753-F633EA22-D756-4680-A90D-68CDE5DC9FDBQ37982202-4956A229-C57E-4C72-A899-42DD21AD07C5Q38006740-40BDB434-AD13-441A-A23A-29EF264EF8BCQ38049066-90A47025-84B3-4EE3-A62C-19C53AC43B10Q38586930-38164744-DE38-48FE-BB7E-A44BDEEF079FQ40666385-3B9B004A-9506-4D1B-BF71-1D9BCDBFA9E0Q50154700-771C568B-5A0E-4ED4-819C-2B6AD63AAD93Q51299251-57F42552-FBC0-4A34-8332-2C2AEE019906Q51334679-39A67E39-A11A-4BD2-9F52-24A57132544BQ58130023-F50C0F33-68F2-462E-90D3-5162DB601EC0Q58775453-ECA427AD-9942-48B5-B6C9-85486AA5884F
P2860
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study p
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The role of niacin in raising ...... ine characteristics of study p
@ast
The role of niacin in raising ...... ine characteristics of study p
@en
type
label
The role of niacin in raising ...... ine characteristics of study p
@ast
The role of niacin in raising ...... ine characteristics of study p
@en
prefLabel
The role of niacin in raising ...... ine characteristics of study p
@ast
The role of niacin in raising ...... ine characteristics of study p
@en
P2860
P921
P1476
The role of niacin in raising ...... ine characteristics of study p
@en
P2093
AIM-HIGH Investigators
P2860
P304
P356
10.1016/J.AHJ.2010.12.007
P407
P577
2011-02-02T00:00:00Z